PCVX - Company ID 0001649094
Vaxcyte, Inc. trades as PCVX and has a market capitalization of $8.56 B, making it the #1052 largest US-listed company by market value. This page tracks Vaxcyte, Inc. through 681 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-23 |
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive ® (PCV21) and Prevnar 20 ® (PCV20), the Current Standard-of-Care PCVs
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com . A replay of the webcast will be available for approximately 30 days following the conference call.
The largest companies sharing Vaxcyte, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Vaxcyte, Inc. (PCVX) has a market capitalization of $8.56 B as of 2026-07-09, ranking #1052 among US-listed companies.
In its latest fiscal year Vaxcyte, Inc. reported a net loss of $766.63K.